Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2018.01641 Immunology Correction Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 Ozkaynak M. Fevzi 1 * Gilman Andrew L. 2 London Wendy B. 3 Naranjo Arlene 4 Diccianni Mitchell B. 5 Tenney Sheena C. 4 Smith Malcolm 6 Messer Karen S. 5 Seeger Robert 7 Reynolds C. Patrick 8 Smith L. Mary 9 Shulkin Barry L. 10 Parisi Marguerite 11 Maris John M. 12 Park Julie R. 11 Sondel Paul M. 13 Yu Alice L. 5 14 * for the Children’s Oncology Group (COG) 1New York Medical College, Valhalla, NY, United States 2Levine Children’s Hospital, Charlotte, NC, United States 3Dana Farber Cancer Institute and Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States 4Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, United States 5Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States 6National Cancer Institute, Bethesda, MD, United States 7Children’s Hospital Los Angeles, University Southern California, Los Angeles, Los Angeles, CA, United States 8Texas Tech University Health Sciences Center, Lubbock, TX, United States 9United Therapeutics, Silver Spring, MD, United States 10St. Jude’s Children’s Research Hospital, Memphis, TN, United States 11Seattle Children’s Hospital, University of Washington School of Medicine, Seattle, WA, United States 12Children’s Hospital of Philadelphia, Philadelphia, PA, United States 13University of Wisconsin Carbone Cancer Center, Madison, WI, United States 14Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan

Edited and Reviewed by: Frontiers in Immunology Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: M. Fevzi Ozkaynak, mehmet_ozkaynak@nymc.edu; Alice L. Yu, a1yu@ucsd.edu

Specialty section: This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

 16 07 2018 2018 9 1641 02 07 2018 03 07 2018 Copyright © 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu. 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, et al. Front Immunol (2018) 9:1355. doi: 10.3389/fimmu.2018.01355 neuroblastoma immunotherapy anti-GD2 chimeric antibody cytokines safety cytokine biomarkers

In the original article, we neglected to include the funder NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation.

The revised “Funding” should read:

This work was supported by ARRA grant from the National Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation and COG SDC grant U10CA180899.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.